Literature DB >> 12393715

Identification of a novel class of human adherent CD34- stem cells that give rise to SCID-repopulating cells.

Selim Kuçi1, Johannes T Wessels, Hans-Jörg Bühring, Karin Schilbach, Michael Schumm, Gabriele Seitz, Jürgen Löffler, Peter Bader, Paul G Schlegel, Dietrich Niethammer, Rupert Handgretinger.   

Abstract

Here we describe the in vitro generation of a novel adherent cell fraction derived from highly enriched, mobilized CD133(+) peripheral blood cells after their culture with Flt3/Flk2 ligand and interleukin-6 for 3 to 5 weeks. These cells lack markers of hematopoietic stem cells, endothelial cells, mesenchymal cells, dendritic cells, and stromal fibroblasts. However, all adherent cells expressed the adhesion molecules VE-cadherin, CD54, and CD44. They were also positive for CD164 and CD172a (signal regulatory protein-alpha) and for a stem cell antigen defined by the recently described antibody W7C5. Adherent cells can either spontaneously or upon stimulation with stem cell factor give rise to a transplantable, nonadherent CD133(+)CD34(-) stem cell subset. These cells do not generate in vitro hematopoietic colonies. However, their transplantation into nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice induced substantially higher long-term multilineage engraftment compared with that of freshly isolated CD34(+) cells, suggesting that these cells are highly enriched in SCID-repopulating cells. In addition to cells of the myeloid lineage, nonadherent CD34(-) cells were able to give rise to human cells with B-, T-, and natural killer-cell phenotype. Hence, these cells possess a distinct in vivo differentiation potential compared with that of CD34(+) stem cells and may therefore provide an alternative to CD34(+) progenitor cells for transplantation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12393715     DOI: 10.1182/blood-2002-03-0711

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  19 in total

1.  Comparative analysis of proliferative potential and clonogenicity of MACS-immunomagnetic isolated CD34+ and CD133+ blood stem cells derived from a single donor.

Authors:  D Freund; J Oswald; S Feldmann; G Ehninger; D Corbeil; M Bornhäuser
Journal:  Cell Prolif       Date:  2006-08       Impact factor: 6.831

2.  Isolation of cultured endothelial progenitor cells in vitro from PBMCs and CD133(+) enriched cells.

Authors:  Weihong Zheng; Yafeng Wan; Xiaopeng Ma; Xingrui Li; Zhifang Yang; Qian Yin; Jilin Yi
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-02-14

3.  CD271 antigen defines a subset of multipotent stromal cells with immunosuppressive and lymphohematopoietic engraftment-promoting properties.

Authors:  Selim Kuçi; Zyrafete Kuçi; Hermann Kreyenberg; Erika Deak; Kathrin Pütsch; Sabine Huenecke; Chandrasekhar Amara; Stefanie Koller; Eva Rettinger; Manuel Grez; Ulrike Koehl; Hatixhe Latifi-Pupovci; Reinhard Henschler; Torsten Tonn; Dorothee von Laer; Thomas Klingebiel; Peter Bader
Journal:  Haematologica       Date:  2010-02-23       Impact factor: 9.941

4.  COMPARE-AMI trial: comparison of intracoronary injection of CD133+ bone marrow stem cells to placebo in patients after acute myocardial infarction and left ventricular dysfunction: study rationale and design.

Authors:  Samer Mansour; Denis-Claude Roy; Vincent Bouchard; Ba Khoi Nguyen; Louis Mathieu Stevens; Francois Gobeil; Alain Rivard; Guy Leclerc; François Reeves; Nicolas Noiseux
Journal:  J Cardiovasc Transl Res       Date:  2009-11-12       Impact factor: 4.132

5.  Human CD133-derived bone marrow stromal cells establish ectopic hematopoietic microenvironments in immunodeficient mice.

Authors:  Benjamin Bakondi; Jeffrey L Spees
Journal:  Biochem Biophys Res Commun       Date:  2010-08-16       Impact factor: 3.575

6.  CD133 identifies a human bone marrow stem/progenitor cell sub-population with a repertoire of secreted factors that protect against stroke.

Authors:  Benjamin Bakondi; Issei S Shimada; Anthony Perry; James R Munoz; Joni Ylostalo; Alan B Howard; Carl A Gregory; Jeffrey L Spees
Journal:  Mol Ther       Date:  2009-08-18       Impact factor: 11.454

7.  Efficient in vitro generation of adult multipotent cells from mobilized peripheral blood CD133+ cells.

Authors:  S Kuçi; Z Kuçi; S Schmid; G Seitz; I Müller; A Dufke; T Leimig; G Murti; R Jurecic; M Schumm; P Lang; G Bruchelt; P Bader; T Klingebiel; D Niethammer; R Handgretinger
Journal:  Cell Prolif       Date:  2008-02       Impact factor: 6.831

Review 8.  Establishing humanized mice using stem cells: maximizing the potential.

Authors:  D Bernard; M Peakman; A C Hayday
Journal:  Clin Exp Immunol       Date:  2008-04-24       Impact factor: 4.330

Review 9.  Concise review: bone marrow mononuclear cells for the treatment of ischemic syndromes: medicinal product or cell transplantation?

Authors:  Natividad Cuende; Laura Rico; Concha Herrera
Journal:  Stem Cells Transl Med       Date:  2012-05-03       Impact factor: 6.940

Review 10.  The stem cell revolution: on the role of CD164 as a human stem cell marker.

Authors:  Suzanne M Watt; Hans-Jörg Bühring; Paul J Simmons; Andrew W C Zannettino
Journal:  NPJ Regen Med       Date:  2021-06-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.